Revista de la Sociedad Argentina de Diabetes
TRATAMIENTO FARMACOLÓGICO DE LA DIABETES MELLITUS PARA PACIENTES CON ENFERMEDAD RENAL
Resumen
Palabras clave
Texto completo:
PDFReferencias
National Kidney Foundation. KDOQI Clinical practice guideline for diabetes and CKD: 2012 update. Am J Kidney Dis 2012; 60(5):850-886.
American Diabetes Association. Standards of Medical Care in Diabetes 2017. Diabetes Care 2017; 40 (Suppl 1).
Metformin-containing drugs: Drug Safety Communica- tion. Revised warnings for certain patients with reduced kidney function https://www.fda.gov/Safety/MedWatch/ SafetyInformation/SafetyAlertsforHumanMedical- Products/ucm494829.htm?source5govdelivery&utm_ medium5email&utm_source5govdelivery.revisado 20/03/2017
Frechtel G, Litwak L, et al. Guía del tratamiento de la diabetes mellitus tipo 2. Sociedad Argentina de Diabetes. Revista de la Sociedad Argentina de Diabetes 2010; 44 (5): 366-367.
Buse JB, DeFronzo RA, Rosenstock J, et al. The primary glucose-lowering effect of metformin resides in the gut, not the circulation: results from short-term pharmacoki- netic and 12-week dose-ranging studies. Diabetes Care 2016; 39(2):198-205.
Davies M, Chatterjee S, Khunti K. The treatment of type 2 diabetes in the presence of renal impairment: what we should know about newer therapies. Clinical Pharmacology: Advances and Applications 2016; 8: 61-81.
Cherney DZI, Perkins BA, Soleymanlou N, et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 2014; 129(5): 587-597.
Heerspink HJL, Desai M, Jardine M, et al. Canagliflo- zin slows progression of renal function decline independently of glycemic effects. J Am Soc Nephrol 2017; 28:368-375.
Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016; 375(4):311-22.
Cooper ME, Perkovic V, McGill JB, et al. Kidney disease end points in a pooled analysis of individual patient-level data froma large clinical trials program of the dipep- tidyl peptidase 4 inhibitor linagliptin in type 2 diabetes. Am J Kidney Dis 2015; 66(3):441-9.
Sola D, Rossi L, Schianca GPC, et al. Sulfonylureas and their use in clinical practice. AMS 2015; 11(4): 840-848.
Mbanya JC, Al-Sifiri S, Abdel-Rahim A, et al. Incidence of hypoglycemia in patients with type 2 diabetes treated with gliclazide versus DPP-4 inhibitors during Ramadan: A meta-analytical approach. Diabetes Res Clin Pract 2015 Aug; 109(2):226-32.
Monami M, Balzi D, Lamanna C, et al. Are sulphonylu- reas all the same? A cohort study on cardiovascular and cancer-related mortality. Diabetes Metab Res Rev 2007 Sep; 23(6):479-84.
Tuttle K. Bakris GL, Bilous RW, et al. Diabetic kidney disease: a report from an ADA Consensus Conference. Diabetes Care 2014; 37:2864-2883.
Davies M, Bain SC, Atkin SL, et al. Efficacy and safety of liraglutide vs placebo as add-on to glucose-lowering therapy in patients with type 2 diabetes and moderate renal impairment (LIRA-RENAL): a randomized clinical trial. Diabetes Care 2016; 39(2):222-230.
Marso S, Daniels GH, Brown-Frandsen K, et al. Liraglu- tide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016 July 28; 375(4): 311-322.
Senior P, Escalada J, Halimi S, et al. Glycemic con- trol and hypoglycemia benefits with insulin glargine 300 U/mL (Gla-300) extend to people with type 2 diabe- tes and mild-to-moderate renal impairment. Canadian Journal of Diabetes 2016; 40(5): S47.
DOI: http://dx.doi.org/10.47196/diab.v51i3.107
Copyright (c) 2018 Revista de la Sociedad Argentina de Diabetes (SAD)
